apitegromab (apitegromab) by Catalent Pharma Solutions, LLC: new drug for further processing listing
apitegromab (apitegromab) by Catalent Pharma Solutions, LLC: new drug for further processing listing. Dated 54 days ago, it serves as a historical benchmark. Score 25/100. As of 2026-11-03, from U.S. FDA National Drug Code (NDC) Directory via openFDA.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Free preview: all 9 published fields of this record are shown below. Locked: 103 related FdaNdcDirectoryPulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Generic name | apitegromab |
| NDC | 11014-0769 |
| Labeler | Catalent Pharma Solutions, LLC |
| Product type | DRUG FOR FURTHER PROCESSING |
| Approval pathway | DRUG FOR FURTHER PROCESSING |
| Dosage form | INJECTION, SOLUTION |
| Active ingredients | APITEGROMAB 150 mg/3mL |
| Marketing start | 2026-09-11 |
| Package configurations | 1 |
| Peer records CSV (104 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch apitegromab (apitegromab) by Catalent Pharma Solutions, LLC
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock apitegromab (apitegromab) by Catalent Pharma Solutions + all 104 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Product · Labeler · Pathway · Form · Listed · official source URL
- Source agency: U.S. FDA National Drug Code (NDC) Directory via openFDA
- Record date: 2026-09-11
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top FdaNdcDirectoryPulse records (DRUG FOR FURTHER PROCESSING first): Lutetium (Lu 177) chloride (Lutetium (Lu 177) chloride) by C · Olibanum 1X (Olibanum 1X) by US Tinctures, LLC · ACYCLOVIR (ACYCLOVIR) by Isomedix Operations Inc · Water (Water) by Siegfried Hameln GmbH · Exosomes (Exosomes) by Regenerative Cell Research Institute · Browse all by state and category →
LIVE PUBLIC DATA Source: U.S. FDA National Drug Code (NDC) Directory via openFDA · Last refreshed: Tue, 03 Nov 2026 18:09:00 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: apitegromab (apitegromab) by Catalent Pharma Solutions, LLC and 104 DRUG FOR FURTHER PROCESSING peers
- DRUG FOR FURTHER PROCESSING FdaNdcDirectoryPulse records like this one: 104
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every DRUG FOR FURTHER PROCESSING peer: $20,800 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
25 / 100 Launch Signal Score
- Injectable: hospital and 503B relevance.
What is the FdaNdcDirectoryPulse record for apitegromab (apitegromab) by Catalent Pharma Solutions, LLC?
apitegromab by Catalent Pharma Solutions, LLC: new drug for further processing listing (DRUG FOR FURTHER PROCESSING) starting 2026-09-11.
How does apitegromab (apitegromab) by Catalent Pharma Solutions, LLC compare to other FdaNdcDirectoryPulse records?
It is 54 days old; check the official source for later updates before acting. Its Launch Signal Score of 25/100 is modest; treat it as background rather than a priority.
apitegromab (apitegromab) by Catalent Pharma Solutions, LLC vs. top 3 peers
| Organization | Location | Record date |
|---|---|---|
| apitegromab (apitegromab) by Catalent Pharma Solutions, LLC | DRUG FOR FURTHER PROCESSING | 2026-09-11 |
| Water (Water) by Siegfried Hameln GmbH | DRUG FOR FURTHER PROCESSING | 2026-10-19 |
| Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. | DRUG FOR FURTHER PROCESSING | 2026-09-22 |
| zilganersen (zilganersen) by Patheon Italia S.p.A. | DRUG FOR FURTHER PROCESSING | 2026-09-04 |
Related records
- Ifosfamide
- Rifadin
- Oxygen
- Water (Water) by Siegfried Hameln GmbH: new drug for further processing listing
- Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.: new drug for further processing listing
- zilganersen (zilganersen) by Patheon Italia S.p.A.: new drug for further processing listing
- teduglutide (teduglutide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
How to monitor apitegromab (apitegromab) by Catalent Pharma Solutions, LLC and peer other records
Get new FdaNdcDirectoryPulse records like apitegromab (apitegromab) by Catalent Pharma Solutions, LLC by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.